Loading…
Employees: 1,332
Size Lanzhou Foci Pharmaceutical (002644.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $582M, the 3495th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.60 on 6 Nov 2026.
Performance Over six months the shares fell 9.4%, against -23.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 2.6% over the last twelve months (peer median -3.0%); the operating margin is 5.3% (peer median 13.6%).
Valuation It trades at 3.6× enterprise value to sales against a peer median of 2.7× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.9 points below its cost of capital (8.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥926M | CN¥909M | CN¥966M | CN¥1.16B | CN¥1.04B |
| Revenue growth | — | -6% | -17% | +12% | — |
| Gross profit | CN¥289M | CN¥284M | CN¥266M | CN¥337M | CN¥284M |
| EBITDA | CN¥112M | CN¥98.5M | CN¥95.5M | CN¥122M | CN¥115M |
| Net income | CN¥58.8M | CN¥49.2M | CN¥60.1M | CN¥67.2M | CN¥109M |
| Free cash flow | CN¥293M | CN¥165M | CN¥26.9M | CN¥45.0M | CN¥45.8M |
| Capital expenditure | CN¥33.8M | CN¥18.5M | CN¥13.3M | CN¥22.5M | CN¥41.5M |
| Total debt | CN¥84.5M | CN¥98.4M | CN¥88.4M | CN¥80.1M | CN¥57.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002644.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | -7.8% | 11th highest of 21 |
| 6-month return | -9.4% | -23.2% | 3rd highest of 21 |
| Distance from 52-week high | -31.0% | -40.5% | 4th highest of 21 |
| Revenue growth (TTM) | +2.6% | -3.0% | 8th highest of 19 |
| Operating margin | 5.3% | 13.6% | 9th lowest of 20 |
| EV / Sales | 3.6× | 2.7× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 24.3% | 3.0% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +6.5% | +7.9% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +17.8 pp | -2.0 pp | most demanding of 13 |
| ROIC minus cost of capital | -5.9 pp | -0.2 pp | 4th lowest of 19 |
| EV / EBITDA | 29.9× | 10.4× | most expensive of 6 |
| Net debt / EBITDA | -4.9× | -1.4× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | 3.1× | 1.3% | +1.0% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 5.1× | 4.0% | +18.5% |
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 0.7× | -0.3% | -0.5% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 5.0× | 25.8% | +13.4% |
| Grape King Bio 1707.TW | Taiwan | $361M | -28% | -7% | 20% | 1.0× | -18.9% | +2.3% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |
| Daiken Biomedical 7780.TW | Taiwan | $352M | -24% | n/a | 18% | 3.0× | 0.3% | n/a |